$ELOX
Eloxx Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021821 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.802M $1.995M $3.054M
YoY Change -31.87% -34.68% -29.63%
% of Gross Profit
Research & Development $2.338M $3.488M $7.899M
YoY Change -69.44% -55.84% 94.08%
% of Gross Profit
Depreciation & Amortization $12.00K $15.00K $21.00K
YoY Change -45.45% -28.57% 31.25%
% of Gross Profit
Operating Expenses $4.140M $5.483M $10.95M
YoY Change -59.79% -49.94% 30.18%
Operating Profit -$4.140M -$5.483M -$10.95M
YoY Change -59.79% -49.94% 30.18%
Interest Expense -$209.0K -$341.0K -$667.0K
YoY Change -35.09% -48.88% 138.21%
% of Operating Profit
Other Income/Expense, Net -$201.0K -$747.0K -$667.0K
YoY Change -37.58% 11.99% 138.21%
Pretax Income -$4.341M -$6.230M -$11.62M
YoY Change -59.12% -46.39% 33.72%
Income Tax
% Of Pretax Income
Net Earnings -$4.341M -$6.230M -$11.62M
YoY Change -59.12% -46.39% 33.66%
Net Earnings / Revenue
Basic Earnings Per Share -$1.96 -$2.88 -$5.36
Diluted Earnings Per Share -$1.96 -$2.88 -$134.1K
COMMON SHARES
Basic Shares Outstanding 2.166M 2.166M 2.166M
Diluted Shares Outstanding 2.212M 2.166M 2.166M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.331M $4.904M $39.77M
YoY Change -85.59% -87.67% 117.91%
Cash & Equivalents $4.331M $4.904M $39.77M
Short-Term Investments
Other Short-Term Assets $1.051M $1.499M $2.379M
YoY Change -31.93% -36.99% 39.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.382M $6.403M $42.15M
YoY Change -82.96% -84.81% 111.16%
LONG-TERM ASSETS
Property, Plant & Equipment $130.0K $143.0K $206.0K
YoY Change -31.58% -30.58% 76.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $611.0K $797.0K $1.471M
YoY Change -54.71% -45.82% 258.78%
TOTAL ASSETS
Total Short-Term Assets $5.382M $6.403M $42.15M
Total Long-Term Assets $611.0K $797.0K $1.471M
Total Assets $5.993M $7.200M $43.62M
YoY Change -81.81% -83.49% 114.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.121M $2.434M $2.903M
YoY Change 61.38% -16.16% 492.45%
Accrued Expenses $2.752M $2.230M $4.631M
YoY Change -43.49% -51.85% 58.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.276M $1.536M
YoY Change 102.31%
Total Short-Term Liabilities $21.25M $19.46M $19.17M
YoY Change 8.96% 1.49% 51.1%
LONG-TERM LIABILITIES
Long-Term Debt $3.334M $4.027M $12.12M
YoY Change -70.04% -66.77% 146.69%
Other Long-Term Liabilities $4.000K $6.000K $638.0K
YoY Change -99.19% -99.06% 6280.0%
Total Long-Term Liabilities $3.334M $4.027M $12.12M
YoY Change -70.04% -66.77% 146.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.25M $19.46M $19.17M
Total Long-Term Liabilities $3.334M $4.027M $12.12M
Total Liabilities $24.59M $23.49M $31.93M
YoY Change -21.01% -26.43% 81.23%
SHAREHOLDERS EQUITY
Retained Earnings -$285.0M -$280.6M -$249.9M
YoY Change 9.36% 12.28% 38.6%
Common Stock $266.4M $264.3M $263.8M
YoY Change 0.7% 0.19% 65201.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.60M -$16.29M $11.69M
YoY Change
Total Liabilities & Shareholders Equity $5.993M $7.200M $43.62M
YoY Change -81.81% -83.49% 114.13%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.341M -$6.230M -$11.62M
YoY Change -59.12% -46.39% 33.66%
Depreciation, Depletion And Amortization $12.00K $15.00K $21.00K
YoY Change -45.45% -28.57% 31.25%
Cash From Operating Activities -$2.066M -$6.814M -$9.491M
YoY Change -78.8% -28.21% 23.5%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $11.00K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $14.00K $11.00K
YoY Change
Cash From Investing Activities $14.00K $11.00K -$11.00K
YoY Change -300.0% -200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.428M -7.500M 7.000M
YoY Change -207.14% 454.68%
NET CHANGE
Cash From Operating Activities -2.066M -6.814M -9.491M
Cash From Investing Activities 14.00K 11.00K -11.00K
Cash From Financing Activities 1.428M -7.500M 7.000M
Net Change In Cash -624.0K -14.30M -2.502M
YoY Change -93.6% 471.66% -61.05%
FREE CASH FLOW
Cash From Operating Activities -$2.066M -$6.814M -$9.491M
Capital Expenditures $0.00 $0.00 $11.00K
Free Cash Flow -$2.066M -$6.814M -$9.502M
YoY Change -78.79% -28.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-31326
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
577-5300
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ELOX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2166356
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4904000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19207000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
261000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
261000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1238000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
6403000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20129000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
143000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
654000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
825000
CY2023Q1 us-gaap Assets
Assets
7200000
CY2022Q4 us-gaap Assets
Assets
21123000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3020000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2230000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1536000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3980000
CY2023Q1 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
12535000
CY2022Q4 us-gaap Due To Affiliate Current
DueToAffiliateCurrent
12535000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
667000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2023Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
58000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
45000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19460000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23091000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4027000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8557000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
135000
CY2023Q1 us-gaap Liabilities
Liabilities
23493000
CY2022Q4 us-gaap Liabilities
Liabilities
31783000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2166356
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2166356
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
22000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264303000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263706000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280618000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274388000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-16293000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7200000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21123000
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3488000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7899000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1995000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3054000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5483000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
10953000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5483000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10953000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-747000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-667000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6230000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.36
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.36
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166356
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166356
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166275
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166275
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6230000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-11620000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
597000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
922000
CY2023Q1 us-gaap Depreciation
Depreciation
15000
CY2022Q1 us-gaap Depreciation
Depreciation
21000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
171000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
177000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
120000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
124000
CY2023Q1 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
13000
CY2022Q1 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
270000
CY2023Q1 elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
406000
CY2022Q1 elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
577000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1169000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-586000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1525000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-569000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
434000
CY2023Q1 elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-174000
CY2022Q1 elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-175000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6814000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9491000
CY2023Q1 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
11000
CY2022Q1 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2023Q1 elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
0
CY2022Q1 elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
7000000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7500000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14303000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2502000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19468000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42567000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5165000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40065000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4904000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39768000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
261000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
297000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5165000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40065000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
430000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
297000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
597000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6230000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-16293000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11686000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-280600000
CY2023Q1 us-gaap Depreciation
Depreciation
15000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
180000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
143000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2023Q1 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
307000
CY2022Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
366000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
672000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
93000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
259000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1238000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
331000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
349000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
188000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2988000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1106000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2022Q1 us-gaap Depreciation
Depreciation
21000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
CY2023Q1 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1576000
CY2022Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1544000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
144000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
750000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
215000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2023Q1 elox Accrued Interest On Debt
AccruedInterestOnDebt
81000
CY2022Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
146000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
214000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
134000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2230000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
906000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
256000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
4744000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1536000
CY2023Q1 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4027000
CY2023Q1 elox Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
RoyaltiesPercentageOfNetSalesBasedOnActualAmountOfFunding
0.06
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
249403
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
105.87
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
195895
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.27
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
15638
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.41
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
429660
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.59
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M7D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
109601
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
171.38
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M3D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
597000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
922000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6230000
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
485000
CY2022Q1 us-gaap Interest Expense Other
InterestExpenseOther
404000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
168000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
14000
CY2023Q1 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
406000
CY2022Q1 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
CY2023Q1 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
13000
CY2022Q1 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
270000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-747000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-667000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166356
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166356
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166275
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166275
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.36
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.36
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
430681
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
311445

Files In Submission

Name View Source Status
elox-20230331_pre.xml Edgar Link unprocessable
elox-20230331_cal.xml Edgar Link unprocessable
0000950170-23-021821-index-headers.html Edgar Link pending
0000950170-23-021821-index.html Edgar Link pending
0000950170-23-021821.txt Edgar Link pending
0000950170-23-021821-xbrl.zip Edgar Link pending
elox-20230331.htm Edgar Link pending
elox-20230331.xsd Edgar Link pending
elox-ex10_1.htm Edgar Link pending
elox-ex31_1.htm Edgar Link pending
elox-ex31_2.htm Edgar Link pending
elox-ex32_1.htm Edgar Link pending
elox-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
elox-20230331_def.xml Edgar Link unprocessable
elox-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elox-20230331_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending